Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated With Bispecific Antibodies for R/R Multiple Myeloma

Interactive Practice Guide

The expanding armamentarium of therapies for relapsed/refractory (R/R) multiple myeloma (MM) shifts the therapy selection process from a simple algorithmic approach to an individualized approach that requires consideration of the nature of relapse, previous therapies, treatment-related toxicities, as well as patient comorbidities and preferences. But many clinicians lack knowledge around the MOAs of novel therapies, including bispecific antibodies which have a unique set of toxicities. Ensuring optimal treatment outcomes for patients with R/R MM requires a well-coordinated multidisciplinary/multispecialty team to have a clear understanding of these adverse reactions and strategies to monitor and mitigate treatment-related adverse events associated with bispecific antibodies. This learning hub provides multidisciplinary clinicians with the education and resources needed to effectively translate the latest evidence into routine clinical practice.

Faculty: Beth Faiman PhD, Rebecca LaRue, PharmD, Hans Lee, MD

Release Date: February 03, 2025

Expiration Date: February 03, 2026